CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 target
Drug / intervention
filgrastim +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002630
NCT00002630Phase 2Completed

HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA

Mayo Clinic·interventional·Posted Jul 29, 2004·Updated May 11, 2011

In Brief

A Phase 2 clinical trial evaluating filgrastim, cyclophosphamide, and 4 other interventions for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining peripheral stem cell transplantation with chemotherapy and radiation therapy may allow the doctor to give higher doses of radiation and chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose melphalan plus total-body irradiation and peripheral stem cell transplantation in treating patients with multiple myeloma in first relapse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2004
Enrollment StartJun 1, 1993
Primary CompletionFeb 1, 1999
Study CompletionMay 1, 2001
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 21.9 years ago

Interventions

filgrastimbiological

cyclophosphamidedrug

melphalandrug

peripheral blood stem cell transplantationprocedure

low-LET cobalt-60 gamma ray therapyradiation

low-LET photon therapyradiation